I'm LongbridgeAI, I can summarize articles.FMS.US rose 2.3% this week to close at $22.68, outperforming the S&P 500 by about 2.77 percentage points. The week was not a straight line, with an intraweek range of 8.32%. It opened Monday at $21.88 and edged up to $21.94. Tuesday dipped to a low of $20.91 before closing at $21.41 on heavy volume of roughly 6.21m shares. Prices recovered through Wednesday and Thursday, and Friday finished at $22.68, near the week’s high of $22.73.
The Week
FMS.US rose 2.3% this week to close at $22.68, outperforming the S&P 500 by about 2.77 percentage points. The week was not a straight line, with an intraweek range of 8.32%. It opened Monday at $21.88 and edged up to $21.94. Tuesday dipped to a low of $20.91 before closing at $21.41 on heavy volume of roughly 6.21m shares. Prices recovered through Wednesday and Thursday, and Friday finished at $22.68, near the week’s high of $22.73. The pattern was a pullback followed by a steady recovery.
Key Events
The company’s main story this week was the US kidney care national plan and its own product push. On 21 October, Fresenius Medical Care welcomed the new US kidney care national plan; the Trump administration launched the strategy the same day, and the stock slipped. The company then announced the US launch of multiFiltratePRO™ on 21 and 22 October, an FDA-cleared critical care kidney system. On the research side, a report on 19 October linked GLP-1 use to lower mortality in dialysis patients. Separately, managing body member Martin Fischer bought about EUR 50,440 worth of shares on 19 October.
Analyst Ratings
Several brokers updated views this week. J.P. Morgan and UBS kept sell ratings, Deutsche Bank gave a hold, and DZ BANK stayed at buy. Across the dataset, 7 institutions cover the stock: 1 buy, 3 hold, 2 under and 1 sell. The consensus rating is hold, with a consensus target of $23.85, about 5.2% above the $22.68 close. Individual targets range from $17.33 to $37.92, showing wide dispersion. Within the healthcare services industry, the stock ranks 28th out of 53 names by broker rating.
The Week Ahead
The first half of next week brings a run of US macro data: Dallas Fed manufacturing business activity on 26 October, and on 27 October durable goods orders, FHFA house prices, the Case Shiller 20-city home price index, new home sales, the Richmond Fed composite index and consumer confidence. On the company side, Fresenius Medical Care reports fiscal Q3 2026 results before market open on 3 November, with consensus revenue estimated around $5.512bn.
In Short
The stock finished higher even as the US kidney care plan stirred sentiment. Broker views skew toward hold, with the consensus target only about 5.2% above spot, while the wide target range signals real disagreement. Valuation looks moderate at about 12.1x P/E and 0.92x P/B. In the latest session, large-lot money was a net buyer while medium and small lots were net sellers. The next test is the early-November earnings print, and whether revenue and profit can support current levels.
This article is generated by LongbridgeAI from market data, for information only and not investment advice.